MedDataX Logo

Succinylcholine or Rocuronium for Rigid Bronchoscopy Under General Anesthesia

NCT ID: NCT01579864

Last Updated: 2016-11-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Myorelaxation is generally used as a part of general anesthesia for interventional rigid bronchoscopy. Succinylcholine is most often used because its short duration of action but rocuronium can be used since sugammadex permits a rapid and complete reversal of the neuromuscular block. The aim of ths study is to compare both agents.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

succinylcholine

Succinylcholine 1 mg/kg and a second dose if necessary.

Group Type ACTIVE_COMPARATOR

succinylcholine

Intervention Type DRUG

Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue

Rocuronium

rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary

Group Type EXPERIMENTAL

rocuronium

Intervention Type DRUG

rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

succinylcholine

Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue

Intervention Type DRUG

rocuronium

rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients scheduled for an interventional rigid bronchoscopy under general anesthesia

Exclusion Criteria

* pregnant woman or woman of childbearing age,
* morbid obesity,
* drug allergy,contra-indication to succinylcholine, rocuronium, sugammadex, propofol, remifentanil,
* history of central neurological or brain damage,
* psychotropic treatment,
* pacemaker,
* renal failure,
* disease of the neuromuscular junction.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hopital Foch

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Morgan Le Guen, MD

Role: PRINCIPAL_INVESTIGATOR

Hopital Foch

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Foch

Suresnes, Île-de-France Region, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-000370-59

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2011/05

Identifier Type: -

Identifier Source: org_study_id